Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Metabolic
A peptidic triple-receptor agonist studied in metabolic and endocrinology research.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Synthetic peptide (acylated, 39 residues)
Molecular formula
C221H342N46O68
Molecular weight
~4,731 Da
CAS number
2381089-83-2
Amino acids
39
Fatty acid chain
C20 diacid
Modification
Aib at positions 2 and 20; α-methyl-Leu at position 13; C-terminal amide; Lys17-linked C20 fatty-diacid acylation via a γ-Glu/AEEA linker.
A single-peptide triple agonist built on a GIP/GLP-1/glucagon hybrid scaffold that engages three class B GPCRs — the GIP receptor (GIPR), the GLP-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Cryo-EM structures of LUV RT bound to each receptor–Gs complex reveal a continuous α-helical conformation in which the N-terminal segment inserts into the receptor's transmembrane bundle and the central segment contacts extracellular loops. Non-standard residues (Aib, α-methyl-Leu) confer protease resistance; the C20 fatty-diacid side chain confers reversible albumin binding, extending circulatory half-life.
Lyophilized
20°C (-80°C long term)
powder typically stable ~24 months.
Aliquot to avoid freeze-thaw; protect from light; keep sealed and dry.
Reviews
Gutgesell RM, Nogueiras R, Tschöp MH, Müller TD. (2024). Diabetes Therapy — Review of dual and triple incretin receptor agonist therapies in metabolic research
Misra S, et al. (2025). J Basic Clin Physiol Pharmacol — Systematic review of LUV RT Phase 2 clinical study data
Systematic review & meta-analysis (2025). PubMed — Systematic review and meta-analysis of LUV RT multi-dose study data
Reviews
Pasqualotto E, et al. (2024). Metabolism Open — Systematic review and meta-analysis of LUV RT
Doggrell SA. (2023). Expert Opin Investig Drugs — Review of LUV RT pharmacology and development
Kaur M, Misra S. (2024). Eur J Clin Pharmacol — Review of LUV RT triple-agonist pharmacology in metabolic research
Ray A. (2023). Expert Opin Investig Drugs — Review of LUV RT as a triple incretin receptor agonist
Tetelbaum L, Mullally JA, Frishman WH. (2024). Cardiol Rev — Review of LUV RT triple-agonist pharmacology in metabolic research
Sinha B, Ghosal S. (2025). Obesity (Silver Spring) — Bayesian network meta-analysis of incretin agonist classes including LUV RT
Clinical
Coskun T, et al. (2025). Lancet Diabetes & Endocrinology — Phase 2 multi-dose substudy examining metabolic endpoints
Giblin K, et al. (2026). Diabetes, Obesity and Metabolism — Phase 3 multi-trial program design and rationale paper
Sanyal AJ, et al. (2024). Nature Medicine — Phase 2a randomized, placebo-controlled hepatic imaging study
Urva S, et al. (2023). Diabetes, Obesity and Metabolism — Study of LUV RT and gastric emptying
Rosenstock J, et al. (2023). The Lancet — Phase 2 randomized, placebo- and active-controlled multi-dose study
Jastreboff AM, et al. (2023). NEJM — Phase 2 randomized, placebo-controlled multi-dose study (NCT04881760)
Urva S, et al. (2022). The Lancet — Phase 1b multiple-cohort pharmacokinetic and pharmacodynamic study
Primary research
Briand F, et al. (2025). Obesity — Preclinical metabolic study of LUV RT in a diet-induced rodent metabolic model
Marathe SJ, et al. (2025). npj Metabolic Health and Disease — Preclinical study of LUV RT in a mouse cancer model
Li W, et al. (2024). Cell Discovery — Cryo-EM structural study of LUV RT bound to GLP-1R, GIPR, and GCGR
Regmi A, Roell W. (2023). STAR Protocols — In vitro adipocyte lipolysis protocol with LUV RT
Coskun T, et al. (2022). Cell Metabolism — Discovery and translational characterization of LUV RT as a triple receptor agonist
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| LUV RTThis page | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (dual GLP-1R/GIPR agonist; acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| AOD-9604 | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
| MOTS-c | Mitochondrial-derived peptide (16 residues) | ~2,175 g/mol | 1627580-64-6 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods